Ghana's National Health Insurance Excludes Diabetes Drugs It Lists
Ghana's National Health Insurance Scheme lists diabetes medicines among the treatments it covers. Many insured patients still buy those same medicines with cash. The distance between the list and the pharmacy counter is where chronic care in Ghana quietly breaks down, and it is a gap that repeats across low- and middle-income health systems.
A List That Does Not Match Care
The NHIS medicines list names metformin, several sulfonylureas, and insulin among the products the scheme will reimburse. That list is the promise. The shelves at a district hospital are the reality. When a patient arrives with a valid NHIS card and a prescription for metformin, the drug may be there, or it may not.
Insured patients frequently pay out of pocket anyway. A pharmacy attendant in a regional hospital may explain that the facility has not received its allocation, and the patient can either wait or walk to a private counter down the road. Most walk. The scheme covers the encounter in principle, not the tablet in hand.
The gap lands hardest on working-age adults. Type-2 diabetes is most often diagnosed between the thirties and fifties, when people are earning and supporting households. A monthly medicine bill competes directly with school fees and rent, and the condition is lifelong.
This is not a problem unique to Ghana. Across sub-Saharan Africa, health systems that cover chronic diseases on paper often struggle to deliver them in practice. The World Health Organization has estimated that essential medicines for noncommunicable diseases are available in only about a third of public facilities in low-income countries, though the figure varies widely by country and survey method. In Ghana, the NHIS has expanded coverage since its inception, but the operational gap for chronic care remains.
How the NHIS Medicines List Works
The scheme is funded mainly through a national health insurance levy on selected goods and services, plus contributions from formal-sector workers and premium payments from some informal-sector members. Money flows to district mutual schemes and accredited facilities, which then claim reimbursement for covered care.
The medicines list is revised infrequently. It is not a live document that tracks market prices. When the cedi weakens against the dollar, as it has repeatedly over the past decade, the cost of imported insulin and many generic tablets rises faster than the reimbursement rate paid to facilities.
Metformin is cheap by global standards and usually appears on the list. Insulin is more expensive, requires cold storage, and is more likely to be the drug that patients are told to buy outside. A related piece on this site describes how Indonesia caps specialist referrals for diabetes care, a different design choice facing a similar chronic-disease burden.
The Gap Between Policy and Purchase
Facilities stock what their budgets allow. A district hospital that has not received its quarterly reimbursement in full will prioritize drugs it can afford in volume. Antimalarials and antibiotics move quickly and treat acute illness. A diabetes medicine that one patient takes every day for decades is easier to defer.
Rural clinics report frequent stockouts of one or more diabetes medicines. When the clinic is empty, patients are told to buy outside. Private pharmacies fill the breach, often at prices set by import costs and local demand rather than by any national reference price.
Transport adds a second layer. A patient in a rural district may travel an hour or more to reach a facility that stocks insulin, only to find it unavailable and be sent to a town pharmacy. That round trip can cost more than the medicine itself, and it is a cost the scheme does not reimburse.
Consider the case of a 52-year-old trader in Kumasi, in the Ashanti Region, who was diagnosed with type-2 diabetes three years ago. She holds a valid NHIS card. Each month, she visits her district hospital for a check-up and a prescription for metformin and insulin. On a good month, the hospital has both medicines. On a bad month, which she says happens more often than not, the pharmacy is out of insulin. She then takes a tro-tro to a private pharmacy in the city center, where a month's supply of insulin can cost her between 80 and 120 cedis—roughly a fifth of her monthly income. She has skipped doses when money is tight, and she knows the risks. Her story is typical of many patients managing chronic conditions under the NHIS.
What Chronic Care Costs Patients
Monthly insulin for a person with type-2 diabetes can consume a large share of a modest household income, particularly when combined with test strips and syringes. Estimates of the exact burden vary by region and by whether the patient uses a public facility or a private pharmacy, but the direction is consistent.
Missed doses become emergency visits. A patient who skips insulin for a week to save money may arrive at a hospital with dangerously high blood glucose. That admission costs the system far more than the missed doses would have, and it is the pattern that makes chronic-disease financing a system-wide problem rather than an individual one.
Complications drain households over years. Kidney damage, vision loss, and foot ulcers require specialist care that is concentrated in a few urban centres. This site has argued that screening guidelines assume a colonoscopy within reach, and the same assumption problem applies to diabetes care that presumes a functioning supply chain.
Reform Options Already on the Table
Ghana has discussed a chronic care package that would ring-fence funding for a defined set of long-term conditions. The idea is to separate chronic-disease medicines from the general reimbursement pool so that a facility cannot quietly deprioritize them. Whether such a package would be funded at a level that matches demand is the open question.
Pooled procurement is the other lever. Buying metformin and insulin at national or regional volume could lower unit prices, but it requires reliable forecasting and storage capacity that many districts lack. Insulin cold-chain failures would waste any savings from bulk purchasing.
Community refills could reduce the travel burden. Letting trained community health workers dispense stable oral medicines for diabetes, with periodic clinician review, would cut the number of trips a patient must make. Digital claims data could flag which districts are running short before patients discover it at the counter.
Each approach carries trade-offs. Ring-fencing protects chronic care but can starve acute services if the allocation is fixed. Pooled procurement lowers prices but centralizes risk: a single forecasting error can empty shelves nationwide. Community refills improve access but require supervision to avoid inappropriate dispensing. No single fix addresses both the financing gap and the supply-chain fragility that patients experience as a monthly crisis.
Steps for Patients and Advocates
Ask the facility for the current NHIS medicines list and check whether your prescription appears on it. If a medicine is listed but unavailable, request the reason in writing and keep the receipt for any cash purchase.
Request a generic alternative at the pharmacy when a branded product is quoted. Metformin and several sulfonylureas have well-established generic versions, and the price difference can be substantial.
Join a diabetes association or patient group that coordinates bulk buying. Group purchasing does not solve the supply problem, but it can lower the per-unit cost for members who are already paying cash.
Report stockouts to the district health directorate and to the NHIS district office. A pattern of documented shortages is harder to dismiss than a single complaint, and it feeds into the data that reform proposals depend on.
Push for a dedicated chronic-disease budget line at the district level. Without a protected allocation, diabetes medicines compete with every other line item and tend to lose.
This article is informational and does not constitute personalised medical or financial advice. Patients should consult a qualified clinician about their own treatment and coverage options.
